Condition: Adult T-Cell Leukemia/Lymphoma (ATLL) · Sponsor: Otsuka Medical Devices Co., Ltd. Japan
This study aims to evaluate the tolerability of OJP-001, a therapeutic system combining photodynamic therapy (PDT) using OMD-001 and extracorporeal circulation therapy using OJE-001 and OJC-001, in patients with adult T-cell leukemia/lymphoma (ATL). The study will also investigate the recommended dose and pharmacokinetics of OMD-001, as well as the efficacy and safety of OJP-001.
This description comes directly from the study's public registry record.
Kentaro Ishinabe · +81363617459 · OtsukaRegistry-CT@otsuka.jp
Always discuss trial participation with your own doctor first.
| National Kyushu Cancer Center | Fukuoka, Fukuoka, Japan | Recruiting |
| Sapporo Hokuyu Hospital | Sapporo, Hokkaido, Japan | Recruiting |
| Imamura general hospital | Kagoshima, Kagoshima-ken, Japan | Recruiting |
| University of Miyazaki Hospital | Miyazaki, Miyazaki, Japan | Recruiting |
| Nagasaki University Hospital | Nagasaki, Nagasaki, Japan | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07075328